Interleukin 12 in cancer treatment

Folia Biologica

Volumn 57, Issue 1, 2011, Pages 1-2

  Bubeník, Jan ^a,b  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23;

CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; ELECTROPORATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MELANOMA CELL; MULTIPLE MYELOMA; NATURAL KILLER T CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TH1 CELL;

EID: 79952659833     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Anwer, K., Barnes, M. N., Fewell, J., Lewis, D. H., Alvarez, R. D. (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther. 17, 360-369.
2. Berraondo, P., Prieto, J., Gonzalez-Aseguinolaza, G. (2009) Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9, 62-71.
3. Bubeník, J. (1996) Gene transfer for immunotherapy of cancer (Editorial). Gene Ther. 3, 944-945.
4. Bubeník, J., Den Otter, W., Huland, E. (2000) Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol. Immunother. 49, 116-122.
5. Bubeník, J. (2008) Genetically modified cellular vaccines for therapy of human papillomavirus type 16 ( HPV 16)-associated tumours. Curr. Cancer Drug Targets 8, 180-186.
6. Bubenik, J., Šimová, J. (2009) Genetically modified cellular vaccines against human papilloma virus type 16 (HPV 16)-associated tumours: adjuvant treatment of minimal residual tumour disease after surgery/chemotherapy. J. BUON 14 (Suppl.), S169-S174.
7. Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K.. E., Messina, J. L., Heller, R. (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-5903.
8. Dranoff, G. (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22.
9. Engel, M. A., Neurath, M. F. (2010) Anticancer properties of the IL-12 family - focus on colorectal cancer. Curr. Med. Chem. 17, 3303-3308.
10. Engleman, E. G. (2003) Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30, 23-29.
11. Grufman, P., Kärre, K. (2000) Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur. J. Immunol. 30, 1088-1093.
12. Hallaj-Nezhadi, S., Lotfipour, F., Dass, C. (2010) Nanoparticle-mediated interleukin-12 cancer gene therapy. J. Pharm. Pharm. Sci. 13, 472-485.
13. Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J., Elzaouk, L., Pavlovic, J., Moelling, K. (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 16, 35-48.
14. Indrová, M., Bieblová, J., Jandlová, T., Vonka, V., Pajtasz-Piasecka, E., Reinis, M. (2006) Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int. J. Oncol. 28, 253-259.
15. Indrová, M., Bieblová, J., Bubenik, J., Reinis, M. (2008) IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int. J. Oncol. 32, 499-507.
16. Indrová, M., Bieblová, J., Rossowska, J., Kuropka, P., Pajtasz-Piasecka, E., Bubenik, J., Reinis, M. (2009) HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int. J. Oncol. 34, 173-179.
17. Jinushi, M., Tahara, H. (2009) Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 100, 1389-1396.
18. Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S. S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J. A., Nam, S. J., Yang, J. H., Son, Y. I., Baek, C. H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D. W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J. H., Park, M. H., Kong, G. S., Park, E. Y., Kang, Y. K., Bang, Y. J., Paik, N. S., Lee, S. N., Kim, S. H., Kim, S., Robbins, P. D., Tahara, H., Lotze, M. T., Park, C. H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12, 671-684.
19. Klein, J., Hořejší, V. (1997) Immunology, p.721 (Blackwell Science, Oxford).
20. Lacy, M. Q., Jacobus, S., Blood, E. A., Kay, N. E., Rajkumar, S. V., Greipp, P. R. (2009) Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk. Res. 33, 1485-1489.
21. Malvicini, M., Rizzo, M., Alaniz, L., Piñero, F., García, M., Atorrasagasti, C., Aquino, J. B., Rozados, V., Scharovsky, O. G., Matar, P., Mazzolini, G. (2009) A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res. 15, 7256-7265.
22. Sgadari, C., Angiolillo, A. L., Tosato, G. (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87, 3877-3882. (Pubitemid 26129617)
23. Sun, Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., Schadendorf, D. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 5, 481-490. (Pubitemid 28200640)
24. Triozzi, P. L., Strong, T. V., Bucy, R. P., Allen, K. O., Carlisle, R. R., Moore, S. E., Lobuglio, A. F., Conry, R. M. (2005) Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum. Gene Ther. 16, 91-100.
25. Tsung, K., Meko, J. B., Tsung, Y. L., Peplinski, G. R., Norton, J. A. (1998) Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol. 160, 1369-1377.